Kathryn Ruddy, MD, discusses the use of GnRH agonists in breast cancer.
Kathryn Ruddy, MD
Advertisement
Articles by Kathryn Ruddy, MD
Kathryn Ruddy, MD, associate professor of Oncology, Mayo Clinic, discusses the management of central nervous system (CNS) metastases in HER2-positive breast cancer.
Kathryn Ruddy, MD, discusses how genetic testing could impact treatment of patients with breast cancer.
Advertisement
Latest Updated Articles
Dr. Ruddy on the Use of GnRH Agonists in Breast CancerPublished: May 10th 2022 | Updated:
Dr. Ruddy on the Management of CNS Metastases in HER2+ Breast CancerPublished: November 6th 2018 | Updated:
Dr. Ruddy on the Importance of Genetic Testing in Breast CancerPublished: October 13th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5